(redirected from P-glycoprotein)
Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to P-glycoprotein: ABCB1


 (glī′kō-prō′tēn′, -tē-ĭn)
Any of a group of conjugated proteins having a carbohydrate as the nonprotein component.


(ˌɡlaɪkəʊˈprəʊtiːn) ,




(Biochemistry) any of a group of conjugated proteins containing small amounts of carbohydrates as prosthetic groups. See also mucoprotein


(ˌglaɪ koʊˈproʊ tin, -ti ɪn)

any of a group of complex proteins, as mucin, containing a carbohydrate combined with a simple protein.
Also called gly`co•pep′tide (-ˈpɛp taɪd)
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.glycoprotein - a conjugated protein having a carbohydrate component
mucin - a nitrogenous substance found in mucous secretions; a lubricant that protects body surfaces
compound protein, conjugated protein - a protein complex combining amino acids with other substances
erythropoietin - a glycoprotein secreted by the kidneys that stimulates the production of red blood cells
CD4, cluster of differentiation 4 - a glycoprotein that is found primarily on the surface of helper T cells; "CD4 is a receptor for HIV in humans"
CD8, cluster of differentiation 8 - a membrane glycoprotein that is found primarily on the surface of cytotoxic T cells
lectin - any of several plant glycoproteins that act like specific antibodies but are not antibodies in that they are not evoked by an antigenic stimulus
mucoid - any of several glycoproteins similar to mucin
References in periodicals archive ?
27,28) These interactions occur due to AED induction of the CYP3A4 enzyme and effects on the P-glycoprotein (P-gp) efflux pump.
Multidrug resistance (MDR) involves a variety of mechanisms, including increases in P-glycoprotein (P-gp), multi-drug resistance-associated protein (MRP), breast cancer resistance protein (BCRP) and lung resistance protein (LRP), decreases in Topo-II activity, elevation of glutathione S-transferase (GST), and alterations of protein kinase C (PKC) function (6).
Box The function of P-glycoprotein P-glycoprotein is known as a multi-drug resistance protein because it is involved in resistance mechanisms for a number of drugs.
observed that the anti-skin cancer effects of ursolic acid are augmented by P-glycoprotein inhibitors and that ursolic acid and the stilbene resveratrol, a potent antioxidant, work synergistically, although not by blocking P-glycoprotein.
Furthermore, tacrolimus is also a substrate of P-glycoprotein (1).
Located along the inner lining of brain blood vessels, P-glycoprotein directs toxins and pharmaceuticals back into the bodys circulation before they pass into the brain.
Research shows that natural compounds can reverse drug resistance by inhibition of P-glycoprotein, inhibition of glutathione S-transferase drug detoxification system and inhibition of heat-shock proteins.
Background/Aims: Helicobacter pylori is a carcinogenic bacterium that could induce P-glycoprotein expression in the human gastrointestinal tract.
Recommended over-the-counter doses (range = 2-8 mg daily) do not produce opioid effects in the central nervous system because of poor oral bioavailability and P-glycoprotein efflux * of the medication (1); recent reports suggest that large doses (50-300 mg) of loperamide produce euphoria, central nervous system depression, and cardiotoxicity (2-4).
Keywords: Adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1), Polymorphism, post-operative nausea and vomiting, P-glycoprotein (P-gp).
Tumor necrosis factor alpha increases P-glycoprotein expression in a BME-UV in vitro model of mammary epithelial cells.
Background: Modulation of P-glycoprotein (ABCB1) and evaluation of the collateral sensitivity effect are among the most promising approaches to overcome multidrug resistance (MDR) in cancer.